Punctate Anetoderma after Colony-Stimulating Factor 1 Receptor and Programmed Cell Death 1 Blockade with Irradiation: Clinicopathologic Characterization of a Novel Eruption

Julia Dai; Yuanyuan Zha; Corey C. Foster; Jason J. Luke; Steven J. Chmura; Mark D. Hoffman

doi:10.1001/jamadermatol.2021.2049

Punctate Anetoderma after Colony-Stimulating Factor 1 Receptor and Programmed Cell Death 1 Blockade with Irradiation: Clinicopathologic Characterization of a Novel Eruption

Julia Dai, Yuanyuan Zha, Corey C. Foster, Jason J. Luke, Steven J. Chmura, Mark D. Hoffman

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	998-1000
Number of pages	3
Journal	JAMA Dermatology
Volume	157
Issue number	8
DOIs	https://doi.org/10.1001/jamadermatol.2021.2049
State	Published - Aug 2021
Externally published	Yes

ASJC Scopus subject areas

Dermatology

Access to Document

10.1001/jamadermatol.2021.2049

Cite this

@article{1ef3c93d4ad140148ce6bce69fe3c40b,

title = "Punctate Anetoderma after Colony-Stimulating Factor 1 Receptor and Programmed Cell Death 1 Blockade with Irradiation: Clinicopathologic Characterization of a Novel Eruption",

author = "Julia Dai and Yuanyuan Zha and Foster, {Corey C.} and Luke, {Jason J.} and Chmura, {Steven J.} and Hoffman, {Mark D.}",

note = "Funding Information: Conflict of Interest Disclosures: Dr Luke reported receiving personal fees for scientific advisory boards (no stock) from 7 Hills and Spring Bank; receiving personal fees for scientific advisory boards (stock) from Actym Therapeutics, Alphamab Oncology, Arch Oncology, Kanaph Therapeutics, Mavupharma, Onc.AI, Pyxis, and Tempest Therapeutics; receiving compensation for consultancy from AbbVie, Alnylam Pharmaceuticals, Array BioPharma, Bayer, Bristol Myers Squibb, Checkmate, CStone Pharmaceuticals, Eisai, EMD Serono, KSQ Therapeutics, Janssen, Inzen Therapeutics, MacroGenics, Merck, Mersana, Nektar, Novartis, Pfizer, Regeneron, Ribon Therapeutics, Rubius Therapeutics, Silicon Therapeutics, Synlogic Therapeutics, TRex, Werewolf Therapeutics, Xilio Therapeutics, and Xencor; research support from AbbVie, Agios, Array, Astellas, Bristol Myers Squibb, Corvus Pharmaceuticals, EMD Serono, Immatics, Incyte, Kadmon, MacroGenics, Merck, Moderna, Nektar, Numab, Replimune, Rubius Therapeutics, Spring Bank, Synlogic, Takeda, Trishula Therapeutics, Tizona Therapeutics, and Xencor outside the submitted work; and having patents (provisional) for Serial No. 15/612,657 (Cancer Immunotherapy) and PCT/US18/ 36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof). Dr Chmura reported receiving grants from Bristol Myers Squibb, Merck, AstraZeneca, Takeda, and EMD Serono; serving on a scientific advisory board (no stock) for AstraZeneca; receiving compensation for consultancy from RefleXion Medical; and having a spouse receiving salary from Astellas Pharma outside the submitted work. No other disclosures were reported.",

year = "2021",

month = aug,

doi = "10.1001/jamadermatol.2021.2049",

language = "English (US)",

volume = "157",

pages = "998--1000",

journal = "JAMA Dermatology",

issn = "2168-6068",

publisher = "American Medical Association",

number = "8",

}

TY - JOUR

T1 - Punctate Anetoderma after Colony-Stimulating Factor 1 Receptor and Programmed Cell Death 1 Blockade with Irradiation

T2 - Clinicopathologic Characterization of a Novel Eruption

AU - Dai, Julia

AU - Zha, Yuanyuan

AU - Foster, Corey C.

AU - Luke, Jason J.

AU - Chmura, Steven J.

AU - Hoffman, Mark D.

N1 - Funding Information: Conflict of Interest Disclosures: Dr Luke reported receiving personal fees for scientific advisory boards (no stock) from 7 Hills and Spring Bank; receiving personal fees for scientific advisory boards (stock) from Actym Therapeutics, Alphamab Oncology, Arch Oncology, Kanaph Therapeutics, Mavupharma, Onc.AI, Pyxis, and Tempest Therapeutics; receiving compensation for consultancy from AbbVie, Alnylam Pharmaceuticals, Array BioPharma, Bayer, Bristol Myers Squibb, Checkmate, CStone Pharmaceuticals, Eisai, EMD Serono, KSQ Therapeutics, Janssen, Inzen Therapeutics, MacroGenics, Merck, Mersana, Nektar, Novartis, Pfizer, Regeneron, Ribon Therapeutics, Rubius Therapeutics, Silicon Therapeutics, Synlogic Therapeutics, TRex, Werewolf Therapeutics, Xilio Therapeutics, and Xencor; research support from AbbVie, Agios, Array, Astellas, Bristol Myers Squibb, Corvus Pharmaceuticals, EMD Serono, Immatics, Incyte, Kadmon, MacroGenics, Merck, Moderna, Nektar, Numab, Replimune, Rubius Therapeutics, Spring Bank, Synlogic, Takeda, Trishula Therapeutics, Tizona Therapeutics, and Xencor outside the submitted work; and having patents (provisional) for Serial No. 15/612,657 (Cancer Immunotherapy) and PCT/US18/ 36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof). Dr Chmura reported receiving grants from Bristol Myers Squibb, Merck, AstraZeneca, Takeda, and EMD Serono; serving on a scientific advisory board (no stock) for AstraZeneca; receiving compensation for consultancy from RefleXion Medical; and having a spouse receiving salary from Astellas Pharma outside the submitted work. No other disclosures were reported.

PY - 2021/8

Y1 - 2021/8

UR - http://www.scopus.com/inward/record.url?scp=85113334211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85113334211&partnerID=8YFLogxK

U2 - 10.1001/jamadermatol.2021.2049

DO - 10.1001/jamadermatol.2021.2049

M3 - Letter

C2 - 34190956

AN - SCOPUS:85113334211

SN - 2168-6068

VL - 157

SP - 998

EP - 1000

JO - JAMA Dermatology

JF - JAMA Dermatology

IS - 8

ER -

Punctate Anetoderma after Colony-Stimulating Factor 1 Receptor and Programmed Cell Death 1 Blockade with Irradiation: Clinicopathologic Characterization of a Novel Eruption

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this